Want to see SE:KLAR full AI Analyst Report?
KLAR Stock Chart & Stats
kr0.61
>-kr0.01(-0.40%)
At close: 4:00 PM EST
kr0.61
>-kr0.01(-0.40%)
Day’s Range― - ―
52-Week Rangekr0.42 - kr1.33
Previous CloseN/A
Volume243.47K
Average Volume (3M)401.28K
Market Cap
kr189.40M
Enterprise Valuekr278.94M
Total Cash (Recent Filing)kr260.00K
Total Debt (Recent Filing)kr9.70M
Price to Earnings (P/E)―
Beta2.00
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.25
Shares Outstanding245,976,150
10 Day Avg. Volume684,621
30 Day Avg. Volume401,283
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)-31.79
Price to Sales (P/S)13.71
P/FCF Ratio-3.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.1
Revenue Forecast (FY)kr24.00M
Bulls Say, Bears Say
Bulls Say
Proprietary Delivery PlatformKlaria’s mucoadhesive oral film platform is a durable competitive asset: it enables rapid systemic uptake, differentiates products by delivery route, and supports licensing or co-development models. Such platform IP can underpin multiple candidates and long-term partner revenue streams.
Occasional High Gross MarginsReported periods of very high gross margin indicate the underlying product economics can be favorable. If production and scale are managed or commercialization is partnered, high product-level margins could sustainably support profitability once operating spend is reduced or revenues reaccelerate.
Lean Operating StructureA very small headcount implies a lean fixed-cost base and the ability to outsource R&D and manufacturing. Structurally, this reduces ongoing cash burn per activity and can extend runway between financings, making the development program more capital efficient if managed prudently.
Bears Say
Revenue CollapseA ~99% revenue decline is a structural red flag: it erodes commercial foundation, reduces operating leverage, and weakens negotiating position with partners and suppliers. Rebuilding a durable revenue base can take many quarters and threatens near-term viability absent new contracts or funding.
Negative Shareholders' EquityNegative shareholders’ equity reflects cumulative losses exceeding capital, constraining borrowing capacity and increasing refinancing risk. This condition materially limits strategic flexibility, raises dilution likelihood, and makes durable financing terms harder to secure without major structural remedies.
Persistent Operating Cash BurnConsistently negative operating cash flow shows the company cannot self-fund development and is dependent on external financing. This persistent cash burn creates enduring execution risk, compresses runway, and can force unfavorable capital raises that dilute shareholders and disrupt long-term plans.
KLAR FAQ
What was Klaria Pharma Holding AB’s price range in the past 12 months?
Klaria Pharma Holding AB lowest stock price was kr0.42 and its highest was kr1.33 in the past 12 months.
What is Klaria Pharma Holding AB’s market cap?
Klaria Pharma Holding AB’s market cap is kr189.40M.
When is Klaria Pharma Holding AB’s upcoming earnings report date?
Klaria Pharma Holding AB’s upcoming earnings report date is Aug 27, 2026 which is in 47 days.
How were Klaria Pharma Holding AB’s earnings last quarter?
Klaria Pharma Holding AB released its earnings results on May 29, 2026. The company reported -kr0.035 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.035.
Is Klaria Pharma Holding AB overvalued?
According to Wall Street analysts Klaria Pharma Holding AB’s price is currently Overvalued.
Does Klaria Pharma Holding AB pay dividends?
Klaria Pharma Holding AB does not currently pay dividends.
What is Klaria Pharma Holding AB’s EPS estimate?
Klaria Pharma Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Klaria Pharma Holding AB have?
Klaria Pharma Holding AB has 245,976,150 shares outstanding.
What happened to Klaria Pharma Holding AB’s price movement after its last earnings report?
Klaria Pharma Holding AB reported an EPS of -kr0.035 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 0.38%.
Which hedge fund is a major shareholder of Klaria Pharma Holding AB?
Currently, no hedge funds are holding shares in SE:KLAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.) functions as a pharmaceutical enterprise, active both in Sweden and across global territories. Its current portfolio features Sumatriptan for migraine management and Midazolam for combating acute epileptic seizures. Within its pipeline, Klaria is developing Epinephrine/Adrenaline to address severe allergic responses, Naloxone for reversing opioid overdoses, and Ketamine for applications in acute pain and mood disorders. Moreover, the company is actively involved in bringing cannabis/cannabinoid products, including THC and CBD, to market for medical and recreational purposes. Established in 2014, Klaria is headquartered in Uppsala, Sweden.